Mirtazapina Combix (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Combix, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood and functional outcomes.

GNH USA supplies Mirtazapina Combix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Clients benefit from reliable logistics and comprehensive documentation for import and distribution.

Mirtazapine is a tetracyclic antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood. - Depressive episodes in bipolar disorder (adjunctive): helps reduce depressive symptoms when used alongside mood stabilisers. - Treatment‑resistant depression: may be considered when first‑line agents are ineffective.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction - Suicidal thoughts or behaviour - Seizures - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should consider several safety aspects.

- Monitor weight: patients often experience increased appetite and weight gain. - Assess for suicidal ideation: especially during the early treatment phase. - Use caution in hepatic impairment: dose adjustment may be required. - Adjust dose in elderly patients: increased sensitivity to sedative effects. - Avoid abrupt discontinuation: tapering reduces risk of withdrawal symptoms. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): enhanced sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels. - CYP3A4 inhibitors (e.g., ketoconazole): modest increase in exposure. - Alcohol: can intensify central nervous system effects.